Biological Plausibility of Using Plasma Amino Acid Profile Determination as a Potential Biomarker for Pediatric Patients with Mild Traumatic Brain Injuries
Authors:
- Adán Pérez-ArredondoAdán Pérez-Arredondo
- Eduardo Cázares-RamírezEduardo Cázares-Ramírez
- Luis Tristán-LópezLuis Tristán-López
- Carlos Jiménez-GutiérrezCarlos Jiménez-Gutiérrez
- Diana L. Pérez-LozanoDiana L. Pérez-Lozano
- Ivette A. Martínez-HernándezIvette A. Martínez-Hernández
- Valentina Vega-RangelValentina Vega-Rangel
- Hugo F. Narváez-GonzálezHugo F. Narváez-González
- Camilo RiosCamilo Rios
- Marina Martínez-VargasMarina Martínez-Vargas
- Luz NavarroLuz Navarro
- Liliana Carmona-AparicioLiliana Carmona-Aparicio
Open Access
- 9 September 2025
- journal article
- research article
- Published by MDPI AG in Neurology International
- Vol. 17 (9) , 145
Abstract
Background: Amino acid biomarkers have a crucial influence on our understanding of brain injury mechanisms, and their plasma concentrations may indicate neurological damage and recovery patterns. Pediatric mild traumatic brain injury (mTBI) assessment particularly benefits from such molecular indicators, as clinical presentations can be subtle and variable. However, current diagnostic and prognostic tools lack reliable biochemical markers that can track the temporal evolution of injuries and recovery. Methods: We conducted a prospective longitudinal cohort study involving 36 pediatric mTBI patients and 44 controls to characterize the temporal evolution of key amino acids and their derived indices. Blood samples were collected at 3, 6, 12, and 24 h and at 7, 14, and 28 days post-injury, with amino acids quantified using high-performance liquid chromatography. Results: Our analysis revealed significant temporal changes in glutamate, glutamine, and glycine concentrations, with glutamate peaking at day 7 before declining, while glutamine showed steady increases throughout. The GLN/GLU ratio demonstrated an early excitatory imbalance followed by astrocytic compensation, and the GLX ratio indicated progressive recovery. Conclusions: These patterns represent continuous neurochemical processes involving excitotoxicity and glial regulation, suggesting potential utility as biomarkers for mTBI diagnosis and monitoring. While further validation using larger cohorts is needed, these findings provide compelling evidence of the efficacy of using amino acid profiles to track pediatric mTBI progression and recovery.Keywords
Funding Information
- Pediatrics National Institute (E-022, 261721, IN228223, Fellow of the General Direction of Quality and Health Education)
- SECIHTI (E-022, 261721, IN228223, Fellow of the General Direction of Quality and Health Education)
- DGAPA PAPIIT (E-022, 261721, IN228223, Fellow of the General Direction of Quality and Health Education)
- Fellow of the General Direction of Quality and Health Education (E-022, 261721, IN228223, Fellow of the General Direction of Quality and Health Education)
- Programa de Posgrado en Ciencias Médicas, Odontológicas y de la Salud, UNAM (E-022, 261721, IN228223, Fellow of the General Direction of Quality and Health Education)
This publication has 83 references indexed in Scilit:
- Update on the role of S100B in traumatic brain injury in pediatric population: a meta-analysisChild's Nervous System, 2024
- Traumatic brain injury biomarkers in pediatric patients: a systematic reviewNeurosurgical Review, 2021
- Recent advances in traumatic brain injuryJournal of Neurology, 2019
- Traumatic brain injury: neuropathological, neurocognitive and neurobehavioral sequelaePituitary, 2019
- Elevated glutamate and lactate predict brain death after severe head traumaAnnals of Clinical and Translational Neurology, 2017
- Glutamine Synthetase: Role in Neurological Disorders2016
- Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatricsActa Neurochirurgica, 2009
- Neuroproteomics and systems biology‐based discovery of protein biomarkers for traumatic brain injury and clinical validationProteomics – Clinical Applications, 2008
- Reliability of S100B in predicting severity of central nervous system injuryNeurocritical Care, 2007
- Selective Blockade of the mGluR1 Receptor Reduces Traumatic Neuronal Injury in Vitro and Improves Outcome after Brain TraumaExperimental Neurology, 2001